DOCSLIB.ORG

Dementia in China: Epidemiology, Clinical Management, and Research Advances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dementia in China: Epidemiology, Clinical Management, and Research Advances Series Neurological diseases in China 3 Dementia in China: epidemiology, clinical management, and research advances Longfei Jia, Meina Quan, Yue Fu, Tan Zhao, Yan Li, Cuibai Wei, Yi Tang, Qi Qin, Fen Wang, Yuchen Qiao, Shengliang Shi, Yan-Jiang Wang, Yifeng Du, Jiewen Zhang, Junjian Zhang, Benyan Luo, Qiumin Qu, Chunkui Zhou, Serge Gauthier, Jianping Jia, for the Group for the Project of Dementia Situation in China* China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and Lancet Neurol 2019 health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates Published Online of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite September 4, 2019 improved access to health services, inadequate diagnosis and management for dementia is still common, particularly http://dx.doi.org/10.1016/ S1474-4422(19)30290-X in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, This is the third in a Series of but most patients with dementia still receive care at home. Western medicines for dementia symptoms are widely four papers about neurological used in China, but many patients choose Chinese medicines even though they have little evidence supporting efficacy. diseases in China The number of clinical trials of Chinese and western medicines has substantially increased as a result of progress in *Study group listed at the end of research on new antidementia drugs but international multicentre studies are few in number. Efforts are needed to the paper establish a national system of dementia care enhance training in dementia for health professionals, and develop Innovation Center for global collaborations to prevent and cure this disease. Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Introduction In this Review, we highlight the epidemiology, eco­ Medical University, Beijing, Dementia is a leading cause of disability in people older nomic burden, health­service system, and clinical trials of China (Prof J Jia MD, L Jia MD, than 65 years worldwide, including China.1–3 The number Alzheimer’s disease and other dementias in China. We M Quan MD, Y Fu MD, of patients with dementia in China accounts for approxi­ also discuss whether Chinese medicines have potential T Zhao MD, Y Li MS, C Wei MD, Y Tang MD, Q Qin MD, mately 25% of the entire population with dementia efficacy on dementia and, on the basis of progress and F Wang MD, Y Qiao BS); Beijing worldwide,4 creating a huge challenge for policy makers, challenges to date, we propose future priorities regarding Key Laboratory of Geriatric health­care professionals, and family members. In res­ the care of patients with dementia for policy makers, Cognitive Disorders, Beijing, China (Prof J Jia); Clinical Center ponse, over the past 10 years, the Chinese Government clinicians, and researchers in China and worldwide. This for Neurodegenerative Disease and dementia organisations have imple mented a series of Review will not include those with other types of dem­ and Memory Impairment, plans, culminating in the 13th Five­Year Plan to manage entia, such as frontotemporal demen tia, dementia with Capital Medical University, this disease, previous iterations of which have improved Lewy bodies, and Parkinson’s disease dementia, because Beijing, China (Prof J Jia); Center of Alzheimer’s Disease, Beijing the access of patients with dementia to health­care the data were generally not available. Institute for Brain Disorders, services. In part icular, the national pro gramme for train­ Beijing, China (Prof J Jia); ing dementia doctors, the implementation of new Epidemiology Department of Neurology, dementia guidelines,5,6 and the increased availability of Prevalence The Second Affiliated Hospital 7 of Guangxi Medical University, neuroimaging technologies, including MRI and PET, Over the past decade, many studies have focused on the Nanning, China (Prof S Shi MD); have enabled earlier and more accurate diagnosis of prevalence of dementia in China (appendix pp 3–8). A Department of Neurology and patients who might previously have been misdiagnosed or survey done in 1990 suggested that the prevalence of Center for Clinical overlooked. However, the success of these advances differs dementia was 4·60% and Alzheimer’s disease was Neuroscience, Daping Hospital, 15 Third Military Medical between urban and rural areas in China. In rural areas, 2·99% in individuals aged 65 years and older. In 2005, the University, Chongqing, China patients usually have difficulty access ing health services prevalence of Alzheimer’s disease was reported to be (Prof Y J Wang MD); Department (such as dementia specialist, memory clinics, and imag­ 3·5% following a large­sample, population­based survey in of Neurology, Shandong 8 16 Provincial Hospital Affiliated to ing facilities) com pared with patients in urban areas. four regions (with rural and urban areas). Thereafter, Shandong University, Jinan, Additionally, advances in diag nostic technology and many studies were done, but the results showed a broad China (Prof Y Du MD); methods have resulted in changes to diagnostic criteria,9–11 range for dementia prevalence, from 5·0% to 7·7% for Department of Neurology, which might affect the accuracy of epidemiological studies individuals aged 60 years and older and from 2·0% to Henan Provincial People’s and the results of clinical trials undertaken before 13·0% for individuals aged 65 years and older.17–24 However, Hospital, Zhengzhou University People’s Hospital, changes to diagnostic criteria. Since the 1990s, more than many of these surveys were done in single regions with Zhengzhou, China 100 epidemiological studies have been done in China small sample sizes and might not reflect the actual (Prof Ji Zhang MD); Department that have greatly contributed to the knowledge regard­ epidemiology. Two large­sample, multiregion studies have of Neurology, Zhongnan ing dementia prevalence and inci dence.12–14 However, been done, the first in 201425 and the second in 2019.26 Hospital, Wuhan University, Wuhan, China other aspects of the disease remain unclear and might The studies showed that the prevalence of dementia was (Prof Ju Zhang MD); limit the understanding of the disease from a national 5·14% (95% CI 4·71–5·57) in 2014,25 and 5·60% (3·50–7·60) Department of Neurology, perspective. in 201926 for individuals aged 65 years or older. The First Affiliated Hospital, www.thelancet.com/neurology Published online September 4, 2019 http://dx.doi.org/10.1016/S1474-4422(19)30290-X 1 Series Zhejiang University, A meta­analysis of 96 observational studies, published in (7·64%) in patients aged 60 years and older.30 The Hangzhou, China 2018, reported that the overall prevalence of dementia differences in global prevalence might be explained by (Prof B Luo MD); Department of in Chinese people aged 60 years and older was different demen tia survival time, environmental risk Neurology, The First Affiliated 13 Hospital of Xi’an Jiaotong 5·30% (4·30–6·30). The prevalence of dementia and factors and genetic factors, and mortality before the onset University, Xi’an, China Alzheimer’s disease was substantially higher in rural of dementia.31 Moreover, the heterogeneity in research (Prof Q Qu MD); Department of populations than in urban populations (6·05% vs 4·40% methods, including the use of different diagnosticcriteria, Neurology, The First Teaching 32,33 Hospital of Jilin University, for dementia and 4·25% vs 2·44% for Alzheimer’s disease), can affect results regarding dementia prevalence. Changchun, China probably due to the lower edu cational level in rural Thus, further investigation with a consistent method of (Prof C Zhou MD); and regions.25 Age and sex also affect dementia prevalence.12,25,27 diagnosing dementia is needed for confirmation of disease Departments of Neurology and A systematic review of 75 observational studies, published prevalence. Neurosurgery, and Department of Psychiatry, McGill Centre for in 2013, showed that the prevalence of dementia had Few multicentre and large­scale studies have been done Studies in Aging, McGill doubled at 5­year intervals (from the age of 55 to 99 years) on the prevalence of mild cognitive impairment in China University, Montreal, QC, and was higher in women than in men (the ratio of women over the past 10 years (appendix pp 3–8). From 2009 to Canada (Prof S Gauthier MD) to men was 1·65).12 The sex difference in the Alzheimer’s 2015, six studies that used different diagnostic criteria Correspondence to: disease prevalence was even higher (the ratio of women showed mild cognitive impairment prevalence ranging Prof Jianping Jia, Innovation 12 20,34–38 Center for Neurological to men was 2·37), which might be due to hormonal from 9·70% to 23·30% in Chinese individuals. These 28,29 Disorders, Department of differences and brain development factors. The number studies were done in single regions and did not rep­ Neurology, Xuanwu Hospital, of patients with dementia also varies in different geo­ resent the prevalence of mild cognitive impairment on a Capital Medical University, graphical areas; the prevalence of dementia is 5·5% in national scale. Subsequently, a study in multiple regions, Beijing 100053, China [email protected] northern China, 5·2% in central China, 4·8% in southern which included both urban and rural areas, reported China, and 7·2% in western China,
Load more

Recommended publications
  • Cataloguing Chinese Art in the Middle and Late Imperial Eras
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Spring 2010 Tradition and Transformation: Cataloguing Chinese Art in the Middle and Late Imperial Eras YEN-WEN CHENG University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Asian Art and Architecture Commons, Asian History Commons, and the Cultural History Commons Recommended Citation CHENG, YEN-WEN, "Tradition and Transformation: Cataloguing Chinese Art in the Middle and Late Imperial Eras" (2010). Publicly Accessible Penn Dissertations. 98. https://repository.upenn.edu/edissertations/98 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/98 For more information, please contact [email protected]. Tradition and Transformation: Cataloguing Chinese Art in the Middle and Late Imperial Eras Abstract After obtaining sovereignty, a new emperor of China often gathers the imperial collections of previous dynasties and uses them as evidence of the legitimacy of the new regime. Some emperors go further, commissioning the compilation projects of bibliographies of books and catalogues of artistic works in their imperial collections not only as inventories but also for proclaiming their imperial power. The imperial collections of art symbolize political and cultural predominance, present contemporary attitudes toward art and connoisseurship, and reflect emperors’ personal taste for art. The attempt of this research project is to explore the practice of art cataloguing during two of the most important reign periods in imperial China: Emperor Huizong of the Northern Song Dynasty (r. 1101-1125) and Emperor Qianlong of the Qing Dynasty (r. 1736-1795). Through examining the format and content of the selected painting, calligraphy, and bronze catalogues compiled by both emperors, features of each catalogue reveal the development of cataloguing imperial artistic collections.
    [Show full text]
  • In Early Alzheimer's Disease De
    Protocol I8D-MC-AZFD(a) A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study) NCT02972658 Approval Date: 06-Feb-2018 I8D-MC-AZFD(a) Clinical Protocol Page 1 Protocol I8D-MC-AZFD(a) A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study) Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of LY3314814, unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. LY3314814 (Lanabecestat) Study AZFD is a Phase 3 study designed to test whether LY3314814 will slow disease progression in patients with early Alzheimer’s Disease randomized in Study AZES. Eli Lilly and Company Indianapolis, Indiana USA 46285 Protocol Electronically Signed and Approved by Lilly on date provided below. Approval Date: 06-Feb-2018 GMT LY3314814 I8D-MC-AZFD(a) Clinical Protocol Page 2 Table of Contents Section Page 1.
    [Show full text]
  • Congressional-Executive Commission on China Annual
    CONGRESSIONAL-EXECUTIVE COMMISSION ON CHINA ANNUAL REPORT 2007 ONE HUNDRED TENTH CONGRESS FIRST SESSION OCTOBER 10, 2007 Printed for the use of the Congressional-Executive Commission on China ( Available via the World Wide Web: http://www.cecc.gov VerDate 11-MAY-2000 01:22 Oct 11, 2007 Jkt 000000 PO 00000 Frm 00001 Fmt 6011 Sfmt 5011 38026.TXT CHINA1 PsN: CHINA1 2007 ANNUAL REPORT VerDate 11-MAY-2000 01:22 Oct 11, 2007 Jkt 000000 PO 00000 Frm 00002 Fmt 6019 Sfmt 6019 38026.TXT CHINA1 PsN: CHINA1 CONGRESSIONAL-EXECUTIVE COMMISSION ON CHINA ANNUAL REPORT 2007 ONE HUNDRED TENTH CONGRESS FIRST SESSION OCTOBER 10, 2007 Printed for the use of the Congressional-Executive Commission on China ( Available via the World Wide Web: http://www.cecc.gov U.S. GOVERNMENT PRINTING OFFICE 38–026 PDF WASHINGTON : 2007 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 VerDate 11-MAY-2000 01:22 Oct 11, 2007 Jkt 000000 PO 00000 Frm 00003 Fmt 5011 Sfmt 5011 38026.TXT CHINA1 PsN: CHINA1 VerDate 11-MAY-2000 01:22 Oct 11, 2007 Jkt 000000 PO 00000 Frm 00004 Fmt 5011 Sfmt 5011 38026.TXT CHINA1 PsN: CHINA1 CONGRESSIONAL-EXECUTIVE COMMISSION ON CHINA LEGISLATIVE BRANCH COMMISSIONERS House Senate SANDER M. LEVIN, Michigan, Chairman BYRON DORGAN, North Dakota, Co-Chairman MARCY KAPTUR, Ohio MAX BAUCUS, Montana TOM UDALL, New Mexico CARL LEVIN, Michigan MICHAEL M. HONDA, California DIANNE FEINSTEIN, California TIM WALZ, Minnesota SHERROD BROWN, Ohio CHRISTOPHER H.
    [Show full text]
  • Treatment of Alzheimer's Disease and Blood–Brain Barrier Drug Delivery
    pharmaceuticals Review Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery William M. Pardridge Department of Medicine, University of California, Los Angeles, CA 90024, USA; [email protected] Received: 24 October 2020; Accepted: 13 November 2020; Published: 16 November 2020 Abstract: Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of small molecule drugs do not cross the BBB, and ~100% of biologic drugs do not cross the BBB, so BBB drug delivery technology is needed in AD drug development. Second, the pharmaceutical industry has not developed BBB drug delivery technology, which would enable industry to invent new therapeutics for AD that actually penetrate into brain parenchyma from blood. In 2020, less than 1% of all AD drug development projects use a BBB drug delivery technology. The pathogenesis of AD involves chronic neuro-inflammation, the progressive deposition of insoluble amyloid-beta or tau aggregates, and neural degeneration. New drugs that both attack these multiple sites in AD, and that have been coupled with BBB drug delivery technology, can lead to new and effective treatments of this serious disorder. Keywords: blood–brain barrier; brain drug delivery; drug targeting; endothelium; Alzheimer’s disease; therapeutic antibodies; neurotrophins; TNF inhibitors 1. Introduction Alzheimer’s Disease (AD) afflicts over 50 million people world-wide, and this health burden costs over 1% of global GDP [1].
    [Show full text]
  • Natural Antioxidant Anthocyanins—A Hidden Therapeutic Candidate in Metabolic Disorders with Major Focus in Neurodegeneration
    Review Natural Antioxidant Anthocyanins—A Hidden Therapeutic Candidate in Metabolic Disorders with Major Focus in Neurodegeneration Rahat Ullah 1,†, Mehtab Khan 1,†, Shahid Ali Shah 1,2, Kamran Saeed 1 and Myeong Ok Kim 1,* 1 Division of Applied Life Science (BK 21), College of Natural Sciences, Gyeongsang National University, Jinju 52828, Korea; [email protected] (R.U.); [email protected] (M.K.); [email protected] (S.A.S.); [email protected] (K.S.) 2 Department of Chemistry, Sarhad University of Science & Information Technology (SUIT), Peshawar Khyber Pakhtunkhwa 25000, Pakistan * Correspondence: [email protected]; Tel.: +82-55-772-1345; Fax: +82-55-772-2656 † These authors contributed equally to this paper. Received: 7 May 2019; Accepted: 24 May 2019; Published: 28 May 2019 Abstract: All over the world, metabolic syndrome constitutes severe health problems. Multiple factors have been reported in the pathogenesis of metabolic syndrome. Metabolic disorders result in reactive oxygen species (ROS) induced oxidative stress, playing a vital role in the development and pathogenesis of major health issues, including neurological disorders Alzheimer’s disease (AD) Parkinson's disease (PD). Considerable increasing evidence indicates the substantial contribution of ROS-induced oxidative stress in neurodegenerative diseases. An imbalanced metabolism results in a defective antioxidant defense system, free radicals causing inflammation, cellular apoptosis, and tissue damage. Due to the annual increase in financial and social burdens, in addition to the adverse effects associated with available synthetic agents, treatment diversion from synthetic to natural approaches has occurred. Antioxidants are now being considered as convincing therapeutic agents against various neurodegenerative disorders.
    [Show full text]
  • Current Understanding of Alzheimer's Disease Diagnosis and Treatment
    F1000Research 2018, 7(F1000 Faculty Rev):1161 Last updated: 15 AUG 2018 REVIEW Current understanding of Alzheimer’s disease diagnosis and treatment [version 1; referees: 2 approved] Jason Weller 1,2, Andrew Budson1,2 1Department of Neurology, Boston VA Hospital, 150 South Huntington Street, Jamaica Plain, MA, 02130, USA 2Department of Neurology, Boston University School of Medicine, 72 East Concord Street C-309, Boston, MA, USA First published: 31 Jul 2018, 7(F1000 Faculty Rev):1161 (doi: Open Peer Review v1 10.12688/f1000research.14506.1) Latest published: 31 Jul 2018, 7(F1000 Faculty Rev):1161 (doi: 10.12688/f1000research.14506.1) Referee Status: Abstract Invited Referees Alzheimer’s disease is the most common cause of dementia worldwide, with 1 2 the prevalence continuing to grow in part because of the aging world population. This neurodegenerative disease process is characterized version 1 classically by two hallmark pathologies: β-amyloid plaque deposition and published neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon 31 Jul 2018 clinical presentation fulfilling several criteria as well as fluid and imaging biomarkers. Treatment is currently targeted toward symptomatic therapy, although trials are underway that aim to reduce the production and overall F1000 Faculty Reviews are commissioned burden of pathology within the brain. Here, we discuss recent advances in our from members of the prestigious F1000 understanding of the clinical evaluation and treatment of Alzheimer’s disease, Faculty. In order to make these reviews as with updates regarding clinical trials still in progress. comprehensive and accessible as possible, Keywords peer review takes place before publication; the Alzheimer's disease, dementia, amyloid, tau referees are listed below, but their reports are not formally published.
    [Show full text]
  • Doença De Alzheimer: O Que Há De Novo?
    Universidade de Lisboa Faculdade de Farmácia Doença de Alzheimer: o que há de novo? Cristiana Cardoso Dias Mestrado Integrado em Ciências Farmacêuticas 2017 Universidade de Lisboa Faculdade de Farmácia Doença de Alzheimer: o que há de novo? Cristiana Cardoso Dias Monografia de Mestrado Integrado em Ciências Farmacêuticas apresentada à Universidade de Lisboa através da Faculdade de Farmácia Orientador: Doutora Ana Paula Francisco, Professora Auxiliar, Departamento de Química Farmacêutica e Terapêutica 2017 Resumo A Doença de Alzheimer (DA) é a principal causa de demência no mundo. A doença manifesta-se, principalmente, a partir dos 65 anos de idade, através de sintomas como perda da memória, afasia, apraxia, agnosia, alterações da personalidade, depressão, alucinações. Hipóteses quanto à origem e mecanismos fisiopatológicos da doença incluem alterações cerebrais como a acumulação de agregados insolúveis de proteína β-amiloide (βA) e de proteína tau hiperfosforilada, neuroinflamação, disfunção mitocondrial, stress oxidativo, e disfunções ao nível dos sistemas de neurotransmissores. Neste trabalho é apresentada uma compilação dos desenvolvimentos recentes na área da terapêutica direcionada à DA, nomeadamente moléculas desenvolvidas para atuar nos diferentes processos patológicos envolvidos na doença, assim como potenciais novos alvos para futuras intervenções. As terapêuticas mais relevantes para cada um dos tópicos enumerados são exploradas no trabalho. A maioria das moléculas estudadas atua ao nível da βA e da tau, nomeadamente, na diminuição da produção, diminuição da agregação e aumento da eliminação destas. Outros possíveis alvos terapêuticos são a neuroinflamação, o stress oxidativo, as vias de sinalização da insulina, o metabolismo do colesterol. Moléculas que atuam nos sistemas de neurotransmissão estão a ser estudadas maioritariamente como terapêutica sintomática, não alterando a progressão da doença.
    [Show full text]
  • Special Supplement Clinical Trials on Alzheimer’S Disease in Europe Contents
    Issue 31 October 2019 Special Supplement Clinical trials on Alzheimer’s disease in Europe Contents 3 Foreword 4 Understanding clinical trials Contact Alzheimer Europe 6 Clinical Trials Watch 14, rue Dicks L-1417 Luxembourg 13 Recent failed disease-modifying treatment trials +352 29 79 70 16 The academic perspective on recent clinical trials and on +352 29 79 72 www.alzheimer-europe.org the future of AD research [email protected] @AlzheimerEurope 19 Acknowledgements alzheimer.europe 19 Further information and references Alzheimer Europe gratefully acknowledges the grant provided Board by Janssen, which led to the production of this report. Chairperson: Iva Holmerová (Czech Republic) Vice-Chairperson: Charles Scerri (Malta) Honorary Secretary: Jim Pearson (UK – Scotland) Honorary Treasurer: Maria do Rosário Zincke dos Reis (Portugal) th Members Want to fi nd out more about clinical trials at the 29 Helen Rochford-Brennan, Chairperson of the European Working Group of People with Alzheimer Europe Conference #29AEC in The Hague? Dementia (Ireland) Stefanie Becker (Switzerland) Join our special symposium SS3 “Clinical trials Marco Blom (Netherlands) in Alzheimer’s disease” on Thursday 24 October Sabine Jansen (Germany) Pat McLoughlin (Ireland) 2019, from 12.45–13.45 in room Princess Ariane. Sirpa Pietikäinen (Finland) Jesús Rodrigo (Spain) Karin Westerlund (Sweden) Staff Jean Georges, Executive Director Christophe Bintener, Project Offi cer Cindy Birck, Project Offi cer Kate Boor Ellis, Communications Offi cer Angela Bradshaw, Project
    [Show full text]
  • 2018 Chinese Control and Decision Conference (CCDC 2018)
    2018 Chinese Control and Decision Conference (CCDC 2018) Shenyang, China 9-11 June 2018 Pages 1-680 IEEE Catalog Number: CFP1851D-POD ISBN: 978-1-5386-1245-3 1/10 Copyright © 2018 by the Institute of Electrical and Electronics Engineers, Inc. All Rights Reserved Copyright and Reprint Permissions: Abstracting is permitted with credit to the source. Libraries are permitted to photocopy beyond the limit of U.S. copyright law for private use of patrons those articles in this volume that carry a code at the bottom of the first page, provided the per-copy fee indicated in the code is paid through Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. For other copying, reprint or republication permission, write to IEEE Copyrights Manager, IEEE Service Center, 445 Hoes Lane, Piscataway, NJ 08854. All rights reserved. *** This is a print representation of what appears in the IEEE Digital Library. Some format issues inherent in the e-media version may also appear in this print version. IEEE Catalog Number: CFP1851D-POD ISBN (Print-On-Demand): 978-1-5386-1245-3 ISBN (Online): 978-1-5386-1244-6 ISSN: 1948-9439 Additional Copies of This Publication Are Available From: Curran Associates, Inc 57 Morehouse Lane Red Hook, NY 12571 USA Phone: (845) 758-0400 Fax: (845) 758-2633 E-mail: [email protected] Web: www.proceedings.com Technical Papers Session SatA01:Adaptive Control (I) Venue Room01 Date/Time 15:50-17:50 Chair Wei Guan, Shenyang Aerospace Univ. Co-Chair TianNing Chen, Xi'an Jiaotong Univ. 15:50-16:10 SatA01-1 A new variable step size LMS adaptive algorithm 1 Qun Niu, Xi'an Jiaotong Univ.
    [Show full text]
  • Downloaded in PDB Format from Protein Conducted Setting the Maximum Heavy Atom RMSD Data Bank (
    Sarkar et al. Egyptian Journal of Medical Human Genetics (2021) 22:10 Egyptian Journal of Medical https://doi.org/10.1186/s43042-020-00127-8 Human Genetics RESEARCH Open Access Identification of the most potent acetylcholinesterase inhibitors from plants for possible treatment of Alzheimer’s disease: a computational approach Bishajit Sarkar1* , Sayka Alam1†, Tiluttoma Khan Rajib1†, Syed Sajidul Islam1†, Yusha Araf2 and Md. Asad Ullah1 Abstract Background: Being one of the rapidly growing dementia type diseases in the world, Alzheimer’s disease (AD) has gained much attention from researchers in the recent decades. Many hypotheses have been developed that describe different reasons for the development of AD. Among them, the cholinergic hypothesis depicts that the degradation of an important neurotransmitter, acetylcholine by the enzyme acetylcholinesterase (AChE), is responsible for the development of AD. Although, many anti-AChE drugs are already available in the market, their performance sometimes yields unexpected results. For this reason, research works are going on to find out potential anti-AChE agents both from natural and synthetic sources. In this study, 50 potential anti-AChE phytochemicals were analyzed using numerous tools of bioinformatics and in silico biology to find out the best possible anti-AChE agents among the selected 50 ligands through molecular docking, determination of the druglikeness properties, conducting the ADMET test, PASS and P450 site of metabolism prediction, and DFT calculations. Result: The predictions of this study suggested that among the selected 50 ligands, bellidifolin, naringenin, apigenin, and coptisine were the 4 best compounds with quite similar and sound performance in most of the experiments.
    [Show full text]
  • Dementia (Alzheimer's Dementia)
    Dementia Medications: Updates and Current Trends Tonja M. Woods, PharmD, BCGP Alzheimer’s Summit/WyCOA UW School of Pharmacy June 14, 2017 https://www.uwyo.edu/wycoa/ Learning Objectives • At the end of this presentation, participants should be able to…. • Identify current pharmacologic therapies available for the treatment of dementia • Differentiate between medications approved to treat dementia and those not approved • Appreciate the current challenges in the area of research related to treating dementia Pharmacologic Therapy • Cholinesterase Inhibitors • NMDA Receptor • Donepezil - Aricept® Antagonist • Rivastigmine - Exelon® • Memantine - • Galantamine -Razadyne® Namenda® • Combination Product • Donepezil & Memantine - Namzaric® Donepezil - Aricept® • Dose: 5 – 10 mg daily, 23mg daily • Action: • Blocks the breakdown of a chemical in the brain called acetylcholine = INCREASES Ach • Thought to improve memory and cognition • Adverse effects: • Nausea, vomiting, diarrhea, loss of appetite, dizziness, weight loss, bradycardia • Approved to treat all stages of AD Rivastigmine - Exelon® • Dose: • Oral: 1.5 mg twice daily, ↑ to 3-6 mg twice daily • Take with food • Transdermal Patch: 4.6, 9.5, 13.3 mg/day • Action: inhibits acetyl- and butyrylcholinesterase = INCREASES ACh and BCh • Adverse Effects: • nausea and vomiting, anorexia, fatigue, dizziness, muscle weakness, bradycardia • Approved to treat mild to moderate AD Galantamine - Razadyne® • Dose: 4 mg twice daily, ↑ to 12 mg twice daily (ER – once daily) • Take with food • Action: selective, competitive, reversible ACh inhibitor, enhances action of acetylcholine on nicotinic receptors = INCREASES ACh • Adverse Effects: • nausea and vomiting, diarrhea, loss of appetite, weight loss • Caution in severe kidney & liver impairment • Approved for use in mild to moderate AD Memantine - Namenda® • XR Dose: 7mg daily, increase weekly to target dose of 28mg daily.
    [Show full text]
  • Review Article Novel Anti-Alzheimer's Therapeutic Molecules Targeting
    Hindawi Oxidative Medicine and Cellular Longevity Volume 2020, Article ID 7039138, 19 pages https://doi.org/10.1155/2020/7039138 Review Article Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing Md. Sahab Uddin ,1,2 Md. Tanvir Kabir,3 Philippe Jeandet ,4 Bijo Mathew,5 Ghulam Md Ashraf,6,7 Asma Perveen,8 May N. Bin-Jumah ,9 Shaker A. Mousa ,10 and Mohamed M. Abdel-Daim 11,12 1Department of Pharmacy, Southeast University, Dhaka, Bangladesh 2Pharmakon Neuroscience Research Network, Dhaka, Bangladesh 3Department of Pharmacy, Brac University, Dhaka, Bangladesh 4Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences, University of Reims Champagne-Ardenne, PO Box 1039, 51687 Reims Cedex 2, France 5Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, India 6King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia 7Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia 8Glocal School of Life Sciences, Glocal University, Saharanpur, India 9Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11474, Saudi Arabia 10Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, New York, NY 12144, USA 11Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia 12Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, Ismailia 41522, Egypt Correspondence should be addressed to Md. Sahab Uddin; [email protected] Received 15 February 2020; Revised 27 March 2020; Accepted 1 April 2020; Published 29 April 2020 Academic Editor: Fabiana Morroni Copyright © 2020 Md.
    [Show full text]